Lonza and Agennix to collaborate on talactoferrin

Monday, April 16, 2012 12:49 PM

Switzerland-based Lonza and Germany-based Agennix have signed an agreement for the production of Agennix’s talactoferrin.

Talactoferrim is Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI) and is currently in phase III testing for the treatment of non-small cell lung cancer (NSCLC). The FORTIS-M trial, which completed enrollment in March 2011, is evaluating talactoferrin in NSCLC patients whose disease has progressed following two or more prior treatment regimens.  A second Phase III trial, FORTIS-C, is evaluating talactoferrin in combination with the standard chemotherapy regimen, carboplatin/paclitaxel, in first-line NSCLC patients. 

The agreement initiates the process to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch. Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic.

“We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale,” said Rajesh Malik, M.D., CMO and management board member, Agennix. “In anticipation of positive phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply.”

Share:          
CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs